Veterinary Pain Management Drugs Market - 2023-2031
The Veterinary Pain Management Drugs Market was valued at US$ 2.06 billion in 2023 and is anticipated to reach US$ 3.00 billion by 2031, at a CAGR of 0.048 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Veterinary Pain Management Drugs Market.
This report delivers a comprehensive overview of the Veterinary Pain Management Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Veterinary Pain Management Drugs Market. The Veterinary Pain Management Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
Veterinary Pain Management Drugs Market Scope:
By Drug Type
This report delivers a comprehensive overview of the Veterinary Pain Management Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Veterinary Pain Management Drugs Market. The Veterinary Pain Management Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Veterinary Pain Management Drugs Market.
This report delivers a comprehensive overview of the Veterinary Pain Management Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Veterinary Pain Management Drugs Market. The Veterinary Pain Management Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
Veterinary Pain Management Drugs Market Scope:
By Drug Type
- NSAIDS
- Opioids
- Local Anesthetics
- Alpha-2 Agonists
- Disease Modified Osteoarthritis Drugs (DMOAD)
- Oral
- Parenteral
- Topical
- Companion Animal
- Livestock
- Postoperative Pain
- Joint Pain
- Cancer
- Other
- Veterinary Hospitals & Clinics
- Retail Pharmacies
- Online Pharmacies
- Dechra Pharmaceuticals
- Zoetis
- Elanco
- Boehringer Ingelheim
- Vetoquinol S.A.
- Ceva Sante Animale S.A.
- Bayer AG
- Merck Animal Health
- Norbrook Laboratories
- Chanelle Pharma
- Virbac
- Assisi Animal Health
This report delivers a comprehensive overview of the Veterinary Pain Management Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Veterinary Pain Management Drugs Market. The Veterinary Pain Management Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet by Drugs
3.2. Market Snippet by Route of Administration
3.3. Market Snippet by Animal
3.4. Market Snippet by Application
3.5. Market Snippet by Distribution Channel
3.6. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.2. Drivers
4.2.1. Rising Prevalence of Painful and Inflammatory Diseases in Animals
4.2.2. Increasing Initiatives towards Animal Healthcare
4.2.3. Increasing number of companion animal ownership
4.3. Restraints
4.3.1. Side Effects Associated with Drugs
4.3.2. Changes in Distribution Channel
4.4. Opportunity
4.5. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
5.4. Pricing Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY DRUG TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
7.1.2. Market Attractiveness Index, By Drug Type Segment
7.2. NSAIDS*
7.2.1. Introduction
7.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
7.2.3. Meloxicam
7.2.4. Deracoxib
7.2.5. Carprofen
7.2.6. Etodolac
7.2.7. Firocoxib
7.2.8. Others
7.3. Opioids
7.3.1. Morphine
7.3.2. Codeine
7.3.3. Fentanyl
7.3.4. Buprenorphine
7.3.5. Others
7.4. Local Anesthetics
7.4.1. Lidocaine
7.4.2. Bupivacaine
7.4.3. Mepivacaine
7.4.4. Others
7.5. Alpha-2 Agonists
7.5.1. Medetomidine
7.5.2. Xylazine
7.5.3. Romifidine
7.5.4. Others
7.6. Disease Modified Osteoarthritis Drugs (DMOAD)
7.6.1. Others
8. BY ROUTE OF ADMINISTRATION
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
8.1.2. Market Attractiveness Index, By Route of Administration Segment
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
8.3. Parenteral
8.4. Topical
9. BY ANIMAL
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Segment
9.1.2. Market Attractiveness Index, By Animal Segment
9.2. Companion Animal*
9.2.1. Introduction
9.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
9.2.3. Dogs
9.2.4. Cats
9.2.5. Horses
9.2.6. Other Companion Animals
9.3. Livestock
9.3.1. Cattle
9.3.2. Swine
9.3.3. Other Livestock Animals
10. BY APPLICATION
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
10.1.2. Market Attractiveness Index, By Application Segment
10.2. Postoperative Pain*
10.2.1. Introduction
10.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
10.3. Joint Pain
10.3.1. Osteoarthritis
10.3.2. Musculoskeletal Disorders
10.4. Cancer
10.5. Other
11. BY DISTRIBUTION CHANNEL
11.1. Introduction
11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
11.1.2. Market Attractiveness Index, By Distribution Channel Segment
11.2. Veterinary Hospitals & Clinics*
11.2.1. Introduction
11.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. BY REGION
12.1. Introduction
12.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
12.3.8.1. Germany
12.3.8.2. U.K.
12.3.8.3. France
12.3.8.4. Italy
12.3.8.5. Spain
12.3.8.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia Pacific
12.6. The Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
13. COMPETITIVE LANDSCAPE
13.1. Competitive Scenario
13.2. Key Strategies adopted by Manufacturers
13.3. Market Positioning/Share Analysis
13.4. Product Benchmarking
14. COMPANY PROFILES
14.1. Dechra Pharmaceuticals*
14.1.1. Company overview
14.1.2. Procedure portfolio and description
14.1.3. Key highlights
14.1.4. Financial overview
14.2. Zoetis
14.3. Elanco
14.4. Boehringer Ingelheim
14.5. Vetoquinol S.A.
14.6. Ceva Sante Animale S.A.
14.7. Bayer AG
14.8. Merck Animal Health
14.9. Norbrook Laboratories
14.10. Chanelle Pharma
14.11. Virbac
14.12. Assisi Animal Health
15. DATAM INTELLIGENCE
15.1. Appendix
15.2. About Us and Services
15.3. Contact Us
1.1. Research methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet by Drugs
3.2. Market Snippet by Route of Administration
3.3. Market Snippet by Animal
3.4. Market Snippet by Application
3.5. Market Snippet by Distribution Channel
3.6. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.2. Drivers
4.2.1. Rising Prevalence of Painful and Inflammatory Diseases in Animals
4.2.2. Increasing Initiatives towards Animal Healthcare
4.2.3. Increasing number of companion animal ownership
4.3. Restraints
4.3.1. Side Effects Associated with Drugs
4.3.2. Changes in Distribution Channel
4.4. Opportunity
4.5. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
5.4. Pricing Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY DRUG TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
7.1.2. Market Attractiveness Index, By Drug Type Segment
7.2. NSAIDS*
7.2.1. Introduction
7.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
7.2.3. Meloxicam
7.2.4. Deracoxib
7.2.5. Carprofen
7.2.6. Etodolac
7.2.7. Firocoxib
7.2.8. Others
7.3. Opioids
7.3.1. Morphine
7.3.2. Codeine
7.3.3. Fentanyl
7.3.4. Buprenorphine
7.3.5. Others
7.4. Local Anesthetics
7.4.1. Lidocaine
7.4.2. Bupivacaine
7.4.3. Mepivacaine
7.4.4. Others
7.5. Alpha-2 Agonists
7.5.1. Medetomidine
7.5.2. Xylazine
7.5.3. Romifidine
7.5.4. Others
7.6. Disease Modified Osteoarthritis Drugs (DMOAD)
7.6.1. Others
8. BY ROUTE OF ADMINISTRATION
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
8.1.2. Market Attractiveness Index, By Route of Administration Segment
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
8.3. Parenteral
8.4. Topical
9. BY ANIMAL
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Segment
9.1.2. Market Attractiveness Index, By Animal Segment
9.2. Companion Animal*
9.2.1. Introduction
9.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
9.2.3. Dogs
9.2.4. Cats
9.2.5. Horses
9.2.6. Other Companion Animals
9.3. Livestock
9.3.1. Cattle
9.3.2. Swine
9.3.3. Other Livestock Animals
10. BY APPLICATION
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
10.1.2. Market Attractiveness Index, By Application Segment
10.2. Postoperative Pain*
10.2.1. Introduction
10.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
10.3. Joint Pain
10.3.1. Osteoarthritis
10.3.2. Musculoskeletal Disorders
10.4. Cancer
10.5. Other
11. BY DISTRIBUTION CHANNEL
11.1. Introduction
11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
11.1.2. Market Attractiveness Index, By Distribution Channel Segment
11.2. Veterinary Hospitals & Clinics*
11.2.1. Introduction
11.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. BY REGION
12.1. Introduction
12.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
12.3.8.1. Germany
12.3.8.2. U.K.
12.3.8.3. France
12.3.8.4. Italy
12.3.8.5. Spain
12.3.8.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia Pacific
12.6. The Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
13. COMPETITIVE LANDSCAPE
13.1. Competitive Scenario
13.2. Key Strategies adopted by Manufacturers
13.3. Market Positioning/Share Analysis
13.4. Product Benchmarking
14. COMPANY PROFILES
14.1. Dechra Pharmaceuticals*
14.1.1. Company overview
14.1.2. Procedure portfolio and description
14.1.3. Key highlights
14.1.4. Financial overview
14.2. Zoetis
14.3. Elanco
14.4. Boehringer Ingelheim
14.5. Vetoquinol S.A.
14.6. Ceva Sante Animale S.A.
14.7. Bayer AG
14.8. Merck Animal Health
14.9. Norbrook Laboratories
14.10. Chanelle Pharma
14.11. Virbac
14.12. Assisi Animal Health
15. DATAM INTELLIGENCE
15.1. Appendix
15.2. About Us and Services
15.3. Contact Us
